论文部分内容阅读
Hepatocellular carcinoma (HCC) occurs at a rate of 3-5％per year in patients with compensated cirrhosis, and itoften represents the first disease complication and themain cause of death in these patients (1). Surveillance forHCC is recommended by all liver disease associations,as it increases patient survival mainly as a result of earlydiagnosis of the tumour, allowing most patients to conveyto curative treatments (2,3).